Cargando…

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

BACKGROUND: The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with the good clinical outcomes. However, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morimoto, Kenji, Yamada, Tadaaki, Takumi, Chieko, Ogura, Yuri, Takeda, Takayuki, Onoi, Keisuke, Chihara, Yusuke, Taniguchi, Ryusuke, Yamada, Takahiro, Hiranuma, Osamu, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021904/ https://www.ncbi.nlm.nih.gov/pubmed/33833990 http://dx.doi.org/10.3389/fonc.2021.630136

Ejemplares similares

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
por: Onoi, Keisuke, et al.
Publicado: (2020)

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
por: Ishida, Masaki, et al.
Publicado: (2021)

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
por: Morimoto, Kenji, et al.
Publicado: (2021)

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study
por: Tanimura, Keiko, et al.
Publicado: (2021)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer
por: Tanaka, Satomi, et al.
Publicado: (2022)

Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study
por: Seto, Yurie, et al.
Publicado: (2021)

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
por: Morimoto, Kenji, et al.
Publicado: (2022)

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
por: Okura, Naoko, et al.
Publicado: (2020)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
por: Morimoto, Kenji, et al.
Publicado: (2022)

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
por: Katayama, Yuki, et al.
Publicado: (2020)

Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer
por: Seto, Yurie, et al.
Publicado: (2022)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study
por: Yoshimura, Akihiro, et al.
Publicado: (2021)

Tumor Neovascularization and Developments in Therapeutics
por: Katayama, Yuki, et al.
Publicado: (2019)

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions
por: Imabayashi, Tatsuya, et al.
Publicado: (2019)

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
por: Tanimura, Keiko, et al.
Publicado: (2022)

Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report
por: Seto, Yurie, et al.
Publicado: (2023)

Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
por: Shiotsu, Shinsuke, et al.
Publicado: (2022)

Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
por: Takayuki, Nakano, et al.
Publicado: (2018)

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
por: Imabayashi, Tatsuya, et al.
Publicado: (2019)

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
por: Tanimura, Keiko, et al.
Publicado: (2023)

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018)

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
por: Iwasaku, Masahiro, et al.
Publicado: (2023)

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022)

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations
por: Noguchi, Rei, et al.
Publicado: (2023)

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
por: Takei, Shota, et al.
Publicado: (2023)

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)
por: Kawachi, Hayato, et al.
Publicado: (2023)

Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment
por: Uchino, Junji, et al.
Publicado: (2018)

The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status
por: Kaneko, Yoshiko, et al.
Publicado: (2020)

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan
por: Hibino, Makoto, et al.
Publicado: (2022)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
por: Uda, Sayaka, et al.
Publicado: (2022)

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer
por: Nakamura, Ryota, et al.
Publicado: (2023)

A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e1v4rcrtg7cirgspl4jbink31n